MAFPMethoxy arachidonyl fluorophosphonate
Irreversible FAAH inhibitor (IC50 1 to 3 nM); it also inhibits phospholipases A2 and binds CB1 (IC50 20 nM).
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₁H₃₆FO₂P
CID 10429254
- Family
- ECS pharmacological toolEnzyme inhibitor
- Molar mass
- 370.50 g/mol
Updated on
In plain terms
MAFP permanently blocks the enzyme that destroys anandamide. It has been used to study the role of that enzyme, but it also binds the CB1 receptor and inhibits other enzymes, which makes it a powerful but imprecise tool. It has been studied only in cells and tissues; no study in humans was found.
Receptors and activity
Target network
- Blocks or inhibits
- Binds or modulates
The lower the cited value, the closer the target sits to MAFP: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of MAFP.
FAAHFAAH found in 7 regions of the body
- CortexpresentCortical pyramidal neurons1
- Basal gangliapresentStriatal neurons1
- HypothalamuspresentPresent in hypothalamic nuclei1
- CerebellumpresentPurkinje cells and cerebellar layers1
- BrainstempresentInferior olivary nuclei1
- Adipose tissuepresentExpressed in mature adipocytes2
- BonepresentPresent on osteoclasts3
Map sources
- Romero J et al. Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Brain Res Mol Brain Res, 2002 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Rossi F et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009 (new tab)
Cited values
- FAAHInhibitorIC50 = 3 nM75 out of 100
De Petrocellis et al., Biochem Biophys Res Commun 1997 (new tab) · covalent inhibition of anandamide amidohydrolase partially purified from N18TG2 cells (mouse), RBL-1 cells (rat) and pig brain: IC50 of 1 to 3 nM depending on the preparation (upper value retained); about 800-fold more potent than arachidonyl trifluoromethyl ketone on rat brain homogenates (Deutsch 1997)
- CB1Binding (function not established)IC50 = 20 nM62 out of 100
Deutsch et al., Biochem Pharmacol 1997 (new tab) · [3H]CP-55940 displacement (IC50 of 20 nM versus 40 nM for anandamide); preparation not specified in the abstract; irreversible binding; functional effect not established
- iPLA2 (calcium-independent phospholipase A2)InhibitorIC50 = 500 nM · mouse38 out of 100
Lio et al., Biochim Biophys Acta 1996 (new tab) · P388D1 macrophage enzyme: half-maximal inhibition at 0.5 µM after 5 min preincubation at 40 °C; irreversible inhibition
- cPLA2 (phospholipase A2 cytosolique de 85 kDa)Inhibitorno measured value cited
Irreversible active-site-directed inhibitor, recalled as such by Lio et al. 1996; no value in the abstract
Pharmacology
MAFP (methoxy or methyl arachidonyl fluorophosphonate) is an organophosphorus compound built around an arachidonic chain recognised by endocannabinoid enzymes, carrying a reactive fluorophosphonate. First known as an irreversible inhibitor of phospholipases A2 (Lio et al. 1996), it was described in 1997 as a very potent inhibitor of anandamide amidase: about 800 times more potent than arachidonyl trifluoromethyl ketone in rat brain homogenates (Deutsch et al. 1997) and with an IC50 of between 1 and 3 nM, making it the most potent inhibitor described at the time (De Petrocellis et al. 1997). The same Deutsch publication nonetheless flagged its limit: it also binds the CB1 receptor, which it occupies irreversibly with an IC50 of 20 nM, better than anandamide (40 nM). Lio and colleagues had further shown that it also inhibits calcium-independent phospholipase A2 (IC50 0.5 µM) and does not discriminate between the two phospholipases A2, advising caution when it is used in intact cells. A tool meant to isolate the effect of raised anandamide therefore acts on other targets at the same time, which makes results delicate to interpret. These studies concern enzyme and cell preparations; no study in humans was found.
Key sources.
- Deutsch DG et al. Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem Pharmacol, 1997 (new tab)PMID 9065728
- De Petrocellis L et al. Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase. Biochem Biophys Res Commun, 1997 (new tab)PMID 9070224
- Lio YC et al. Irreversible inhibition of Ca(2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. Biochim Biophys Acta, 1996 (new tab)PMID 8695655
- PubChem, MAFP, CID 10429254 (identifiers and properties) (new tab)
History
- Source
- An entirely synthetic compound with no natural occurrence found in the sources consulted. It is described as a biochemical research reagent; no human or veterinary use was found.
Origin
Research tool
No biological pathway: MAFP is a synthetic compound, a fluorophosphonate with an arachidonic chain, unrelated to the plant cannabinoid pathway.
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. It is not listed in the schedules of the 1971 Convention on Psychotropic Substances (INCB Green List, 36th edition, 2025, text reviewed). No marketing authorisation was found.
- France
Not classified: MAFP is not on the ANSM consolidated list of narcotics (updated 16/02/2026) and this fatty acid fluorophosphonate falls within none of the generic families of that list. Its status under other regimes (organophosphorus, toxic chemicals) was not verified here.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Enzyme inhibitor
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Methoxy arachidonyl fluorophosphonate (new tab)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Deutsch DG et al. Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem Pharmacol, 1997 (new tab)PMID 9065728
- De Petrocellis L et al. Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase. Biochem Biophys Res Commun, 1997 (new tab)PMID 9070224
- Lio YC et al. Irreversible inhibition of Ca(2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. Biochim Biophys Acta, 1996 (new tab)PMID 8695655
- PubChem, MAFP, CID 10429254 (identifiers and properties) (new tab)
Identifiers
Names
- Common name
- Methoxy arachidonyl fluorophosphonate
- IUPAC name
- (5Z,8Z,11Z,14Z)-1-[fluoro(methoxy)phosphoryl]icosa-5,8,11,14-tetraene
- Other names
- MAFP · methyl arachidonyl fluorophosphonate
Identifiers
- Formula
- C₂₁H₃₆FO₂P
- PubChem CID
- 10429254(new tab)
- InChIKey
- KWKZCGMJGHHOKJ-ZKWNWVNESA-N
- SMILES
- CCCCC/C=
C\C/C= C\C/C= C\C/C= C\CCCCP(= O) (OC) F
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.